Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
Authors
Keywords
GBM, EGFR, EGFRvIII, Nimotuzumab, Rapamycin
Journal
BMC CANCER
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-04-10
DOI
10.1186/s12885-015-1191-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance
- (2015) Kimmo J. Hatanpaa et al. NEOPLASIA
- EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma
- (2013) Qi-Wen Fan et al. CANCER CELL
- Signal integration by mTORC1 coordinates nutrient input with biosynthetic output
- (2013) Christian C. Dibble et al. NATURE CELL BIOLOGY
- Nimotuzumab Enhances the Radiosensitivity of Cancer Cells In Vitro by Inhibiting Radiation-Induced DNA Damage Repair
- (2013) Yuan-yuan Qu et al. PLoS One
- Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding
- (2013) Arshawn Sami et al. TUMOR BIOLOGY
- Combined temozolomide and radiation as an initial treatment for anaplastic glioma
- (2012) Chee Kian Tham et al. Asia-Pacific Journal of Clinical Oncology
- Molecular Characterization of EGFR and EGFRvIII Signaling Networks in Human Glioblastoma Tumor Xenografts
- (2012) Hannah Johnson et al. MOLECULAR & CELLULAR PROTEOMICS
- Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group
- (2012) Wei Yan et al. NEURO-ONCOLOGY
- The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin
- (2012) Lei Zhao et al. TUMOR BIOLOGY
- EGFR targeting monoclonal antibody combines with an mTOR inhibitor and potentiates tumor inhibition by acting on complementary signaling hubs
- (2012) Roshan James et al. Cancer Medicine
- Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile
- (2011) Greta Garrido et al. CANCER BIOLOGY & THERAPY
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells
- (2011) J. Hu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase I single-dose study of intracavitary-administered Nimotuzumab labeled with 188-Re in adult recurrent high-grade glioma
- (2010) Angel Casaco et al. CANCER BIOLOGY & THERAPY
- FoxM1B Regulates NEDD4-1 Expression, Leading to Cellular Transformation and Full Malignant Phenotype in Immortalized Human Astrocytes
- (2010) Bingbing Dai et al. CANCER RESEARCH
- Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy
- (2010) Gur Pines et al. FEBS LETTERS
- Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
- (2010) Dirk Strumberg et al. INVESTIGATIONAL NEW DRUGS
- Zinc at clinically-relevant concentrations potentiates the cytotoxicity of polysorbate 80, a non-ionic surfactant
- (2010) Tomohiro M. Oyama et al. TOXICOLOGY IN VITRO
- Dissecting the role of mTOR: Lessons from mTOR inhibitors
- (2009) Ryan J.O. Dowling et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Nimotuzumab, an Antitumor Antibody that Targets the Epidermal Growth Factor Receptor, Blocks Ligand Binding while Permitting the Active Receptor Conformation
- (2009) A. Talavera et al. CANCER RESEARCH
- Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity
- (2009) William Kells Boland et al. EXPERT OPINION ON BIOLOGICAL THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started